Article
Biochemistry & Molecular Biology
Beinuo Wang, Ruijie Zhang, Yao Wang, Hang Qian, Di Wu, Binfeng He, Hu Liao
Summary: Overcoming cisplatin-based drug resistance in lung cancer remains a challenge globally. Recent studies have shown that Rab GTPases play a role in multiple aspects of tumor progression, including drug resistance. In this study, a nanosystem was developed using Rab26 siRNA-loaded nanoparticles, which effectively transfected cisplatin-resistant lung cancer cells and induced apoptosis while inhibiting autophagy disruption. The combination therapy of siRab26 knockdown with cisplatin improved antitumor therapy in vitro and in vivo. These findings suggest that siRNP is an effective platform for lung cancer therapy in cases of drug resistance.
Article
Biochemistry & Molecular Biology
Dongxian Zhang, Wanling Lu, Nasser Samadi
Summary: This study reveals the significant role of KIF4A in lung cancer progression, and demonstrates that KIF4A inhibition can enhance the sensitivity of lung cancer cells to doxorubicin through targeting p21 and PI3K/AKT pathway.
CHEMICAL BIOLOGY & DRUG DESIGN
(2023)
Article
Multidisciplinary Sciences
Tian-jiao Song, Xiao-hong Lin, Ping-ting Huang, Yu-qing Chen, Li-min Chen
Summary: Lung cancer is a malignant tumor with high morbidity and mortality rates worldwide. The current chemotherapy for lung cancer is ineffective due to drug resistance. Tripchlorolide (T4), a natural extract, has been found to have immunosuppressive and antitumor effects, making it a potential therapeutic agent for lung cancer. This study investigated the effect of T4 on reducing chemoresistance in lung cancer cells and explored the underlying mechanism. The results showed that T4 can increase the sensitivity of lung cancer cells to cisplatin, a chemotherapy drug, by reducing the expression of AEG-1 protein.
SCIENTIFIC REPORTS
(2022)
Article
Engineering, Multidisciplinary
Shasha Bai, Sainan Cui, Wenhao Wen, Elaine Lai-Han Leung, Jing Bai, Huiyuan Lin, Yongfei Cui, Lei Yang, Zhongqiu Liu, Yuan Zheng, Rong Zhang
Summary: Tan IIA, an active ingredient of Salvia miltiorrhiza, inhibits lung cancer growth by inducing autophagic apoptosis.
Article
Oncology
Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesus M. de la Fuente, Daxiang Cui
Summary: The study developed a nanocage system based on up-conversion nanoparticles for targeted delivery of siRNA to tumor sites, which resulted in tumor suppression effects. The system protected siRNA from degradation while showing stable efficacy and longer survival times.
CANCER BIOLOGY & MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Chunjie Ma, Yu Wang, Wei Chen, Ting Hou, Honglian Zhang, Hongguang Zhang, Xu Yao, Chunhui Xia
Summary: This study examined the effects of TaPcZn-PDT on cytotoxicity, cell viability, apoptosis, pyroptosis, cellular reactive oxygen species (ROS), mitochondrial membrane potential (??m), caspase-1, caspase-3, and nuclear transcription factor-?B (NF?B) in MCF-7 cells. The results showed that TaPcZn-PDT increased cytotoxicity and the percentage of apoptotic and pyroptotic cells, decreased cell viability and ??m, induced ROS production, and activated caspase-1, caspase-3, and NF?B in MCF-7 cells. siRNA targeting caspase-1 attenuated the effects of TaPcZn-PDT on apoptosis, pyroptosis, and the activation of caspase-1, caspase-3, and NF?B in MCF-7 cells. Therefore, caspase-1 plays a regulatory role in the apoptosis and pyroptosis induced by TaPcZn-PDT in MCF-7 cells.
Article
Environmental Sciences
Lulu Niu, Wenwen Li, Xin Chen, Xiaosan Su, Jingjing Dong, Quanyang Liao, Xuhong Zhou, Shaoqing Shi, Ruifen Sun
Summary: The active constituent 1-Monopalmitin (1-Mono) in Mougeotia nummuloides and Spirulina major inhibits the proliferation of lung cancer cells and induces apoptosis through the PI3K/Akt pathway. It also suppresses autophagy, and combining with autophagy inhibitor Chloroquine enhances its cytotoxicity.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Shuai Liu, Xiangyu Sun, Huan Lu, Daiqin Chen, Xue Li, Lei Li, Shenge Su, Zhongpu Zhao, Xinran Cao, Libing Liu, Luhua Lai, Xueguang Lu, Chunying Shu, Chunru Wang, Chunli Bai
Summary: A fullerene-based nanocomplex was designed for the inhalation delivery of siRNA, which protects siRNA against degradation, improves cellular uptake and gene knockdown efficiency, and prolongs pulmonary retention. By packaging PD-L1 siRNA, this nanocomplex significantly inhibits the progression of metastatic lung cancer in a mouse model without obvious adverse events and toxicity. This fullerene-based nanocomplex opens up the possibility of siRNA for treating a diverse range of pulmonary diseases.
Article
Medicine, Research & Experimental
Mohammad Mahdevar, Jafar Vatandoost, Farzad Seyed Forootan, Abbas Kiani-Esfahani, Maryam Esmaeili, Maryam Peymani, Hamid Tavakkoli, Ali Osmay Gure, Mohammad Hossein Nasr Esfahani, Kamran Ghaedi
Summary: The study found that lncRNA SRA is dysregulated in CRC tissue, acting as an oncogene through the OXPHOS pathway and serving as a potential biomarker for identifying CRC subtype with KRAS mutations. KRAS mutant samples had the highest SRA1 expression level. Therefore, lncRNA SRA might be a therapeutic target to inhibit cell proliferation in CRC.
Article
Nanoscience & Nanotechnology
Hailing Yu, Kexin Tang, Zeyu Cai, Xi Lin, Yongquan Huang, Ting Yu, Qianqian Zhang, Qiang Wang, Lili Wu, Lei Yang, Hong Shan, Hui Luo
Summary: In this study, a co-delivery nanosystem based on surface-modified carbon dots was developed, enabling simultaneous delivery of siRNA and doxorubicin with acid-triggered drug release. The carbon dots exhibited enzyme-like activity, oxidizing glutathione and generating reactive oxygen species to enhance therapeutic efficacy. The co-delivery system effectively released siRNA and doxorubicin in tumors, antagonizing MRP1 to overcome drug resistance.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Review
Oncology
Kang Hu, Chao Ma, Ruijie Ma, Qiming Zheng, Yepeng Wang, Nan Zhang, Zhigang Sun
Summary: Kruppel-like factor 6 splice variant 1 (KLF6-SV1) is an up-regulated splice variant in multiple malignancies, inhibiting KLF6 gene function and promoting tumor progression, which is associated with poor prognosis. The progress of KLF6-SV1 research in non-small cell lung cancer (NSCLC) reveals its important role in tumorigenesis, tumor development, and therapy resistance. Targeted silencing of KLF6-SV1 using small interfering RNA shows potential as a novel strategy for managing chemotherapy resistance in NSCLC patients.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Materials Science, Multidisciplinary
Zi-Yao Wang, Jie Mei, Dong-Qi Ni, Sheng-Mei Li, Jin-Min Ye, Shi-Lin Li, Ya-Ling Wang, Ying Liu
Summary: The high incidence and mortality of lung cancer pose a global threat. Clinical trials have shown that mutations in certain genes directly or indirectly affect the progress of lung cancer. As a result, molecular inhibitors have been found to benefit patients in clinical therapy, helping to prolong survival time and showing great potential in lung cancer treatment. siRNA, a nucleic acid molecule, can silence targeted gene translation by binding to mRNA. In this study, siRNA is delivered by coordination with Fe2+ to form a self-assembly structure, with doxorubicin (DOX) and human serum albumin (HSA) used for stabilization. The nanoplatform exhibited good lysosome escape, gene silencing effect, and cytotoxicity, providing new possibilities for co-delivery of siRNA and other molecular or protein drugs.
Article
Genetics & Heredity
Beatrice Tolksdorf, Sina Zarif, Juergen Eberle, Ahmet Hazini, Babette Dieringer, Franziska Jonsson, Florian Kreppel, Jens Kurreck, Henry Fechner
Summary: Silencing of Mcl-1 can overcome TRAIL resistance in melanoma cells and enhance the cytotoxicity of TRAIL-expressing adenovirus. The increase of apoptosis induced by Mcl-1 silencing is the main mechanism for this effect, which occurs in both TRAIL-sensitive and TRAIL-resistant melanoma cells.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2021)
Article
Biochemistry & Molecular Biology
Ankith Sherapura, Vikas H. Malojirao, Prabhu Thirusangu, B. S. Sharath, Shivananda Kandagalla, V. Vigneshwaran, Jurica Novak, Lakshmi Ranganatha, Y. L. Ramachandra, Shrinath M. Baliga, Shaukath Ara Khanum, B. T. Prabhakar
Summary: The study confirms BP-1C as a potential JAK2 specific inhibitor for lung cancer treatment, targeting apoptosis to inhibit tumor cell growth and progression.
Review
Pharmacology & Pharmacy
Rajeswari Raguraman, Santny Shanmugarama, Meghna Mehta, Jo Elle Peterson, Yan D. Zhao, Anupama Munshi, Rajagopal Ramesh
Summary: Lung cancer is often diagnosed at an advanced stage with limited treatment options. RNA binding proteins, particularly Human antigen R (HuR), have been identified as key players in tumorigenesis, including lung cancer. This review explores the role of HuR in lung cancer progression and highlights various approaches, such as small molecule inhibitors, siRNAs, and shRNAs, for inhibiting HuR expression and function. These approaches have shown promising results in reducing tumor growth, invasion, migration, angiogenesis, and metastasis. Nanomedicine-based HuR targeting approaches using siRNA and shRNA delivery hold immense potential for enhancing cancer therapies in lung cancer patients.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Biochemistry & Molecular Biology
Yongwen Li, Hongbing Zhang, Ying Li, Chenlong Zhao, Yaguang Fan, Jinghao Liu, Xin Li, Hongyu Liu, Jun Chen
MOLECULAR CARCINOGENESIS
(2018)
Article
Oncology
Xuebing Li, Xuexia Zhou, Yongwen Li, Lingling Zu, Hongli Pan, Boning Liu, Wang Shen, Yaguang Fan, Qinghua Zhou
Article
Oncology
Yongwen Li, Hongbing Zhang, Yunlong Dong, Yaguang Fan, Ying Li, Chenlong Zhao, Cong Wang, Jinghao Liu, Xin Li, Ming Dong, Hongyu Liu, Jun Chen
Article
Oncology
Yongwen Li, Hongbing Zhang, Hao Gong, Yin Yuan, Ying Li, Cong Wang, Weiting Li, Zihe Zhang, Minghui Liu, Hongyu Liu, Jun Chen
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2018)
Article
Chemistry, Multidisciplinary
Cong Wang, Ying Li, Yong-wen Li, Hong-bing Zhang, Hao Gong, Yin Yuan, Wei-ting Li, Hong-yu Liu, Jun Chen
ACTA PHARMACOLOGICA SINICA
(2018)
Article
Oncology
Minghui Liu, Hongyi Zhang, Ying Li, Rui Wang, Yongwen Li, Hongbing Zhang, Dian Ren, Hongyu Liu, Chunsheng Kang, Jun Chen
Article
Biotechnology & Applied Microbiology
Orgilmaa Regzedmaa, Ying Li, Yongwen Li, Hongbing Zhang, Jin Wang, Hao Gong, Yin Yuan, Weiting Li, Hongyu Liu, Jun Chen
ONCOTARGETS AND THERAPY
(2019)
Article
Oncology
Yunlong Dong, Yongwen Li, Renwang Liu, Ying Li, Hongbing Zhang, Hongyu Liu, Jun Chen
Article
Biology
Ling Cai, Hongyu Liu, Fang Huang, Junya Fujimoto, Luc Girard, Jun Chen, Yongwen Li, Yu-An Zhang, Dhruba Deb, Victor Stastny, Karine Pozo, Christin S. Kuo, Gaoxiang Jia, Chendong Yang, Wei Zou, Adeeb Alomar, Kenneth Huffman, Mahboubeh Papari-Zareei, Lin Yang, Benjamin Drapkin, Esra A. Akbay, David S. Shames, Ignacio I. Wistuba, Tao Wang, Jane E. Johnson, Guanghua Xiao, Ralph J. DeBerardinis, John D. Minna, Yang Xie, Adi F. Gazdar
Summary: This study revealed the connection between immune phenotypes and NE scores, as well as the differences in immune gene expression between classic SCLC and variant SCLC. The research demonstrated the re-expression of MHC I in SCLC upon development of chemoresistance. These findings provide guidance for the design of treatment regimens in SCLC.
COMMUNICATIONS BIOLOGY
(2021)
Letter
Oncology
Ruifeng Shi, Yongwen Li, Hongyu Liu, Jun Chen
Article
Respiratory System
Ying Li, Yongwen Li, Hongbing Zhang, Ruifeng Shi, Zihe Zhang, Hongyu Liu, Jun Chen
Summary: The study revealed that aberrant expression of EML4-ALK leads to activation of the JAK2-STAT signaling pathway, essential for the development of non-small cell lung cancer. Inhibiting EML4-ALK resulted in increased apoptosis in lung cancer cells, while overexpression of EML4-ALK increased cell viability. Additionally, treatment with ALK or JAK-STAT pathway inhibitors significantly decreased cell viability in EML4-ALK-positive lung cancer cells.
BMC PULMONARY MEDICINE
(2021)
Article
Oncology
Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Chen Chen, Hua Huang, Min Gao, Songlin Xu, Peijun Cao, Zihe Zhang, Di Wu, Xuanguang Li, Hongyu Liu, Jun Chen
Summary: Patients with advanced stages of NSCLC have poor 5-year survival rates, highlighting the urgent need for novel biomarkers. The study identified hsa_circ_0043256 as a potential therapeutic target for lung cancer and constructed a circRNA-miRNA-mRNA regulatory network.
Article
Biochemistry & Molecular Biology
Zhenhua Pan, Meidi Zhang, Fengyu Zhang, Hongli Pan, Yongwen Li, Yi Shao, Xin Yuan, Ju Wang, Jun Chen
Summary: This study identified the role of lung adenocarcinoma cancer stem cells (LCSCs) in the progression, metastasis, therapy resistance, and recurrence of lung cancer. LCSCs showed high survival rates and increased expression of the stemness marker CD44. Single-cell RNA sequencing revealed heterogeneous subpopulations of LCSCs with different degrees of differentiation and identified key factors associated with cell dedifferentiation and increased CD44 expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biotechnology & Applied Microbiology
Min Gao, Yongwen Li, Hua Huang, Yaguang Fan, Ruifeng Shi, Lianchun Su, Chen Chen, Xuanguang Li, Guangsheng Zhu, Di Wu, Peijun Cao, Hongyu Liu, Jun Chen, Shirong Kang
Summary: This study demonstrates that genetic variants in PRC2 genes, including rs17171119T>G, rs10898459 T>C, and rs1136258 C>T, are associated with a decreased risk of developing lung cancer.
ONCOTARGETS AND THERAPY
(2023)
Article
Biotechnology & Applied Microbiology
Guanghui Xie, Yongwen Li, Yongjun Jiang, Xian Ye, Jianfeng Tang, Jun Chen
Summary: HIPPI is highly expressed in NSCLC tissues and its RNA interference inhibits NSCLC cell proliferation and tumor growth, attenuates cell migration and invasion, and enhances sensitivity to cisplatin. HIPPI positively regulates key regulators of DNA replication, MCM2, MCM6, and MCM8, highlighting its importance in NSCLC tumor biology.
ONCOTARGETS AND THERAPY
(2021)